Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (559)	3/8/2005 12:39:26 AM
From: former_pgs	Read Replies (1) of 946

One correction to this... i mixed up my "N" adverse events. I believe Bianco was talking about neuropathy, not neutropenia. In today's call, he mentioned that they had not looked at neutropenia yet. I find that odd, since this is a rather prevalent side effect with Taxol and provides an important contrast point (clinically and $$$-wise) between Xyotax and Taxol. I find it even harder to believe that they do not have the data on neutropenia, especially when they've already combed the database for LDH and Ca2+ levels (no CBC data available?). The skeptical side of me wonders if the AE profile of Xyotax did not come out as favorably as they had hoped.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next